Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 4
2005 2
2006 1
2007 2
2008 2
2009 2
2010 3
2011 3
2013 2
2015 3
2016 7
2017 3
2018 5
2019 9
2020 6
2021 11
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Breast Cancer Outcome: What Have We Achieved.
Möbus V, Schmidt M. Möbus V, et al. Breast Care (Basel). 2023 Dec;18(6):419-421. doi: 10.1159/000534589. Epub 2023 Oct 16. Breast Care (Basel). 2023. PMID: 38125922 No abstract available.
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.
Reinisch M, Untch M, Mahlberg R, Reimer T, Hitschold T, Marmé F, Aydogdu M, Schmatloch S, Lück HJ, Schmidt M, Ladda E, Sinn BV, Klare P, Janni W, Jackisch C, Denkert C, Seiler S, Göhler T, Michel L, Burchardi N, Stickeler E, Rey J, Klutinus N, Möbus V, Loibl S. Reinisch M, et al. Among authors: mobus v. Breast. 2022 Dec;66:110-117. doi: 10.1016/j.breast.2022.10.002. Epub 2022 Oct 5. Breast. 2022. PMID: 36223695 Free PMC article. Clinical Trial.
Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
van Mackelenbergh MT, Seither F, Möbus V, O'Shaughnessy J, Martin M, Joensuu H, Untch M, Nitz U, Steger GG, Miralles JJ, Barrios CH, Toi M, Bear HD, Muss H, Reimer T, Nekljudova V, Loibl S. van Mackelenbergh MT, et al. Among authors: mobus v. Eur J Cancer. 2022 May;166:185-201. doi: 10.1016/j.ejca.2022.02.003. Epub 2022 Mar 16. Eur J Cancer. 2022. PMID: 35305453
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial.
Gerber B, Schneeweiss A, Möbus V, Golatta M, Tesch H, Krug D, Hanusch C, Denkert C, Lübbe K, Heil J, Huober J, Ataseven B, Klare P, Hahn M, Untch M, Kast K, Jackisch C, Thomalla J, Seither F, Blohmer JU, Rhiem K, Fasching PA, Nekljudova V, Loibl S, Kühn T. Gerber B, et al. Among authors: mobus v. Cancers (Basel). 2022 Jan 20;14(3):521. doi: 10.3390/cancers14030521. Cancers (Basel). 2022. PMID: 35158789 Free PMC article.
mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease.
Wege AK, Rom-Jurek EM, Jank P, Denkert C, Ugocsai P, Solbach C, Blohmer JU, Sinn B, van Mackelenbergh M, Möbus V, Trumpp A, Marangoni E, Pfarr N, Irlbeck C, Warfsmann J, Polzer B, Weber F, Ortmann O, Loibl S, Vladimirova V, Brockhoff G. Wege AK, et al. Among authors: mobus v. Int J Cancer. 2022 Apr 15;150(8):1357-1372. doi: 10.1002/ijc.33911. Epub 2021 Dec 28. Int J Cancer. 2022. PMID: 34927257 Free article.
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, Link T, Untch M, Jackisch C, Blohmer JU, Fasching PA, Solbach C, Schmutzler RK, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S; GBG and AGO-B. Schneeweiss A, et al. Among authors: mobus v. Eur J Cancer. 2022 Jan;160:100-111. doi: 10.1016/j.ejca.2021.10.011. Epub 2021 Nov 17. Eur J Cancer. 2022. PMID: 34801353 Clinical Trial.
Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update.
Friedrich M, Kühn T, Janni W, Müller V, Banys-Paluchowski M, Kolberg-Liedtke C, Jackisch C, Krug D, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm T, Gerber B, Gluz O, Hanf V, Harbeck N, Heil J, Huober J, Kreipe HH, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Thill M, Ditsch N. Friedrich M, et al. Among authors: mobus v. Geburtshilfe Frauenheilkd. 2021 Oct 22;81(10):e31. doi: 10.1055/a-1674-1114. eCollection 2021 Oct. Geburtshilfe Frauenheilkd. 2021. PMID: 34720743 Free PMC article.
AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update.
Friedrich M, Kühn T, Janni W, Müller V, Banys-Pachulowski M, Kolberg-Liedtke C, Jackisch C, Krug D, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm T, Gerber B, Gluz O, Hanf V, Harbeck N, Heil J, Huober J, Kreipe HH, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Thill M, Ditsch N. Friedrich M, et al. Among authors: mobus v. Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1112-1120. doi: 10.1055/a-1499-8431. Epub 2021 Oct 6. Geburtshilfe Frauenheilkd. 2021. PMID: 34629490 Free PMC article.
Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
Stürken C, Möbus V, Milde-Langosch K, Schmatloch S, Fasching PA, Rüschoff J, Stickeler E, Henke RP, Denkert C, Hanker L, Schem C, Vladimirova V, Karn T, Nekljudova V, Köhne CH, Marmé F, Schumacher U, Loibl S, Müller V. Stürken C, et al. Among authors: mobus v. BMC Cancer. 2021 Sep 15;21(1):1024. doi: 10.1186/s12885-021-08754-z. BMC Cancer. 2021. PMID: 34526003 Free PMC article. No abstract available.
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
Möbus V, Lück HJ, Ladda E, Klare P, Schmidt M, Schneeweiss A, Grischke EM, Wachsmann G, Forstbauer H, Untch M, Marmé F, Blohmer JU, Jackisch C, Huober J, Stickeler E, Reinisch M, Link T, Sinn BV, Janni W, Denkert C, Furlanetto J, Engels K, Solbach C, Schmatloch S, Rey J, Burchardi N, Loibl S; GBG and AGO-B. Möbus V, et al. Eur J Cancer. 2021 Oct;156:138-148. doi: 10.1016/j.ejca.2021.07.033. Epub 2021 Aug 24. Eur J Cancer. 2021. PMID: 34450552 Clinical Trial.
67 results